Merck KGaA MRK
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRK is a good fit for your portfolio.
News
-
Merck KGaA Confirms Outlook After Drop in Sales, Earnings
-
Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia
-
Merck KGaA Expects Organic Sales, Earnings Growth This Year
-
Merck KGaA Supervisory Board Elects Michael Kleinemeier as Chair Until Annual Meeting
-
Merck KGaA Supervisory Board Chairman Wolfgang Buechele to Step Down
-
German stocks rise after ending at a record high
-
Trending: Merck's Multiple Sclerosis Drug Misses Expectations in Late-Stage Trials
-
Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials
Trading Information
- Previous Close Price
- €165.85
- Day Range
- €164.65–168.70
- 52-Week Range
- €134.30–172.40
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €73.35 Bil
- Volume/Avg
- 498,812 / 286,532
Key Statistics
- Price/Earnings (Normalized)
- 22.00
- Price/Sales
- 3.49
- Dividend Yield (Trailing)
- 1.39%
- Dividend Yield (Forward)
- 1.39%
- Total Yield
- 1.30%
Company Profile
Merck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (44% of 2023 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (38%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (17%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Core
- Total Number of Employees
- 62,908
- Website
- https://www.emdgroup.com
Competitors
Valuation
|
Metric
|
MRK
|
TMO
|
DHR
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.00 | 27.62 | 32.78 |
Price/Book Value | 2.75 | 5.01 | 3.67 |
Price/Sales | 3.49 | 5.44 | 8.77 |
Price/Cash Flow | 16.33 | 26.64 | 29.87 |
Price/Earnings
MRK
TMO
DHR
Financial Strength
|
Metric
|
MRK
|
TMO
|
DHR
|
|---|---|---|---|
Quick Ratio | 0.79 | 1.19 | 1.34 |
Current Ratio | 1.42 | 1.70 | 1.85 |
Interest Coverage | 11.32 | 4.83 | 15.85 |
Quick Ratio
MRK
TMO
DHR
Profitability
|
Metric
|
MRK
|
TMO
|
DHR
|
|---|---|---|---|
Return on Assets (Normalized) | 7.55% | 8.69% | 5.15% |
Return on Equity (Normalized) | 13.81% | 18.71% | 8.40% |
Return on Invested Capital (Normalized) | 10.19% | 10.97% | 6.02% |
Return on Assets
MRK
TMO
DHR
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Zvvjbldnt | Gpngff | $79.9 Bil | |
ZTS
| Zoetis Inc Class A | Bvlhkkkly | Xcyx | $79.3 Bil | |
HLN
| Haleon PLC ADR | Pqqtscdx | Gjmxj | $38.1 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Pzjqgrxwk | Hjyc | $18.9 Bil | |
VTRS
| Viatris Inc | Nzjbclbhx | Gdtw | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mckrtwfq | Kxw | $11.7 Bil | |
CTLT
| Catalent Inc | Ltpkylpfl | Zghwh | $10.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Srqfyvdl | Gjvz | $4.2 Bil | |
PRGO
| Perrigo Co PLC | Ttjcklnv | Xgcs | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Nqwhnmvrs | Knyglsb | $3.2 Bil |